TEANECK, N.J., Oct. 16, 2024 /CNW/ -- Cognizant (NASDAQ:CTSH) today announced significant enhancements to its Cognizant Neuro ® AI platform, aimed at enabling enterprises to rapidly discover, ...
In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.
The treatment of metabolic dysfunction-associated steatohepatitis (MASH) has proven challenging, with many compounds failing during development for various reasons. However, with the recent ...
Cognizant Partners with Palo Alto Networks to Deliver AI-Led Cybersecurity Services and Strengthen Security Posture of Global Enterprises ...
6d
Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...
Injectable Drug Market. The global injectable drug market is poised for significant growth, with an estimated valuation of ...
Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical ...
The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...
The U.S.-based drugmaker also plans to provide the companies branded version of the drug, lenacapavir, in 18 countries, such ...
Why Gilead cut a deal with 6 generics companies around a yet-to-be-approved, twice-a-year HIV PrEP drug: "It really is all ...
Gilead Sciences Inc. said it is licensing its twice-yearly experimental HIV prevention drug lenacapavir to six generics ...
Gilead has done similar deals in the past. In 2017, for example, it agreed to license its older HIV drug, bictegravir, through the Medicines Patent Pool. And early in the pandemic, the drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback